---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022608"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-05-13T11:30:40+00:00"
generated_at: "2026-05-13T11:39:25.398560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals Publishes Peer-Reviewed Manuscript on SKNY-1 Preclinical Data

## Summary
- Manuscript titled 'SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors' published in International Journal of Molecular Sciences.
- SKNY-1 oral administration produced approximately 30% reduction in body weight from baseline after six days in the higher-dose group.
- SKNY-1 demonstrated differential CB1 signaling, partial CB2 agonist activity, and selective MAO-B inhibition relative to MAO-A.
- Preclinical findings included normalization of total cholesterol and LDL, increased HDL, reduced hepatic triglycerides, and attenuated compulsive feeding and nicotine-seeking behaviors.
- SKNY-1 has not been approved by the FDA; safety and efficacy not yet established in humans.

## SEC filing metadata
- accession: 0001493152-26-022608
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-05-13T11:30:40+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226022608/0001493152-26-022608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226022608/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022608
- JSON: https://secwatch.observer/filing/0001493152-26-022608.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.